SBIR GRANTS have always been an important factor in financing many early stage biopharma companies. While increasingly competitive in recent years, this non-dilutive funding is often a green light to investors that the emerging company has competitive science and a drive to compete for future funding.
http://lnkd.in/gE-zP6
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022